In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Nuvectis Pharma (NVCT – Research Report), with a price target of $21.00. The company’s shares opened today at $11.67.
Pantginis covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Cytokinetics, and PDS Biotechnology. According to TipRanks, Pantginis has an average return of -8.7% and a 39.68% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nuvectis Pharma with a $21.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Nuvectis Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $5.88 million. In comparison, last year the company had a GAAP net loss of $4.67 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its pipeline products include NXP800, NXP900.
Read More on NVCT:
